Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: A multimodality approach

Internal Medicine Journal

Volumn 34, Issue 4, 2004, Pages 167-175

  Horvath, N ^a,d   Hahn, U ^a   Joshua, D ^b   Dyson, P ^a   Gibson, J ^b   Stevens, J ^a   Rawling, T ^a   Barrow, L ^b   Brown, R ^b   Stephens, S ^a   Gower, G ^a   Norman, J ^a   Mills, B ^c   To, L B ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Nexell Therapeutics Inc   (United States)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

CD34+ selection; in vivo purge; Multiple myeloma; Tandem autotransplantation

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; PARAPROTEIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FOLLOW UP; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; MORTALITY; MULTIPLE MYELOMA; NEUTROPHIL; PRIORITY JOURNAL; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SURVIVAL; THROMBOCYTE; THROMBOCYTE LIFESPAN; TREATMENT WITHDRAWAL; VEIN OCCLUSION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; STEM CELLS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 2442455327     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2004.00552.x     Document Type: Article

References (29)

1. Boccadoro M, Marmont F, Tribaldo M, Avvisati G, Andriani T, Barbui M et al. Multiple myeloma: VMCP/VBAB alternating combination chemotherapy is not superior to melphalan and prednisolone even in high risk patients. J Clin Oncol 1991; 9: 444-8.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-9.
3. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicholson M, Hickish T et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-63.
4. Alexanian R, Dimopoulos M, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-82.
5. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R et al. High-dose therapy for refractory myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-56.
6. Attal M, Harousseau JL, Stoppa AM, Sotto J-J, Fuzibet J-G, Rossi J-F et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
7. Henry JM, Sykes PJ, Brisco MJ, To LB, Juttner CA, Morley AA. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996; 92: 614-19.
8. Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schiffman K, Clift RA et al. High-dose therapy followed by autologous haematopoietic stem cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-56.
9. Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol 1995; 89: 640-42.
10. Bjorkstrand B, Ljungmann P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995; 15: 367-71.
11. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF. Gene-marking to trace the origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-6.
12. Stoppa AM, Bouabdallah R, Chabannon C, Norakovitch G, Vey N, Camerlo J et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor prognosis non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 1722-9.
13. Weaver CH, Zhen B, Schwartzberg LS, Leff R, Magee M, Geier L et al. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 245-51.
14. Johnson R, Owen R, Smith G, Child JA, Galvin M, Newton LJ et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996; 17: 723-7.
15. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-97.
16. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A et al. Concommitant mobilization of plasma cells and haematopoietic progenitors into peripheral blood of multiple myeloma patients - positive selection and transplantation of enriched CD34+ cells to remove circulating tumour cells. Blood 1996; 87: 1625-34.
17. Powles R, Raje N, Cunningham J, Malpas J, Milan S, Horton C et al. Maintenance therapy for remission in myeloma with Intron A and either an autologous bone marrow transplant or peripheral blood cell rescue. Stem Cells 1995; 13: 114-17.
18. To LB, Haylock DN, Thorp DL, Dyson PG, Branford A, Ho JQK et al. The optimisation of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia. Bone Marrow Transplant 1989; 4: 41-7.
19. Dyson PG, Horvath N, Joshua D, Barrow L, Van Holst NG, Brown R et al. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilisation in multiple myeloma. Bone Marrow Transplant 2000; 25: 1175-84.
20. Barlogie B, Jagannath S, Vesole DH, Nauke S, Cheson B, Maltox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-93.
21. Attal M, Harrousseau JL. Randomized trial experience of the Intergroupe Froncophone du Myélome. Semin Hematol 2001; 38: 226-30.
22. Basser RL, To LB, Begley G, Maher D, Juttner CA, Cebon J et al. Rapid haemopoietic recovery after multiple high dose chemotherapy: enhancement of filgrastim-induced progenitor cell mobilisation by recombinant human stem cell factor. J Clin Oncol 1998; 16: 1899-908.
23. Dyson PG, Jackson KA, McClure BJ, Rawling TP, To LB. Increased levels of megakaryocyte progenitors in peripheral blood mobilised by chemotherapy and/or haemopoietic growth factor protocols. Bone Marrow Transplant 1996; 18: 705-12.
24. Bensinger W, Appelbaum F, Rowley S, Sharb R, Sanders J, Lilleby K et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-55.
25. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-41.
26. To LB, Haylock DN, Simmons PJ, Juttner CJ. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58.
27. Testa U, Martucci R, Rutella S, Scambia G, Sica S, Benedetti P et al. Autologous stem cell transplantation: release of early and late growth factors relates with haematopoietic ablation and recovery. Blood 1994; 84: 3532-9.
28. Holyoake TL, Alcorn MJ, Richmond L, Farrell E, Pearson C, Green R et al. CD34+ PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transplant 1997; 19: 1095-101.
29. Haas R, Schmid H, Hahn U, Hohaus S, Goldschmidt H, Murea S et al. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer 1997; 33: 372-8.